MYGN Financial Facts

Research and development expense: 19.4M
Selling, general, and administrative expense: 111.9M
See Full Income Statement

Total current assets: 322.9M
Accounts payable: 19.9M
See Full Balance Sheet

Myriad Genetics Inc. (MYGN) Earnings

  |   Expand Research on MYGN
Next EPS Date 8/5/26 *Est. EPS Growth Rate +100.0% *Last Qtr.
Average EPS % Beat Rate +262.5% Revenue Growth Rate -100.0% *Last Qtr.
Average % Move 1-Wk after EPS +1.5% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
4/30/26 Q126 N/A-$0.07 N/A N/A$203.09M = N/A N/A
2/23/26 Q425 $0.04-$0.02 +$0.06$209.8M$207.17M = Details
11/3/25 Q325 $0.00-$0.01 +$0.01$205.7M$204.97M = Details
8/5/25 Q225 $0.05-$0.01 +$0.06$213.1M$201.91M = Details
5/6/25 Q125 -$0.03-$0.06 +$0.03$195.9M$200.9M = Details
2/24/25 Q424 $0.03$0.03 $0.00$211M$213.31M = Details
11/7/24 Q324 $0.06$0.02 +$0.04$213.3M$210.76M = Details
8/6/24 Q224 N/A-$0.01 N/A N/A$206.44M = N/A N/A